KALAMAZOO, Michigan, USA,
May 2,
2023 /PRNewswire/ -- Stryker (NYSE:SYK), one of the
world's leading medical technology companies, announced today that
it has completed the acquisition of Cerus Endovascular Ltd., a
privately held, commercial-stage, medical device company engaged in
the design and development of neurointerventional devices for the
treatment of intracranial aneurysms. Cerus Endovascular's CE Marked
products, the Contour Neurovascular System and the Neqstent Coil
Assisted Flow Diverter, will expand Stryker's current portfolio of
aneurysm treatment solutions.
Technology for the endovascular treatment of aneurysms has been
foundational to Stryker's Neurovascular division and Cerus
Endovascular's portfolio will address the growing need for
one-and-done intrasaccular aneurysm therapy.
"The acquisition of Cerus Endovascular is highly complementary
to Stryker's Neurovascular business, and strengthens our
hemorrhagic portfolio globally," stated Jim
Marucci, president of Stryker's Neurovascular division. "We
look forward to working with the Cerus team to deliver on our
mission of making healthcare better. Together, we will enable
physicians to treat a broader range of aneurysms."
About Stryker
Stryker is one of the world's leading
medical technology companies and, together with its customers, is
driven to make healthcare better. The company offers innovative
products and services in Medical and Surgical, Neurotechnology,
Orthopaedics and Spine that help improve patient and healthcare
outcomes. Alongside its customers around the world, Stryker impacts
more than 130 million patients annually. More information is
available at www.stryker.com.
Media contact
Lindsay
Harris
Global Director, Digital, Marcom and Events
lindsay.harris@stryker.com
Logo -
https://mma.prnewswire.com/media/339565/4009817/stryker_logo.jpg
View original
content:https://www.prnewswire.co.uk/news-releases/stryker-completes-acquisition-of-cerus-endovascular-301812473.html